The Lobbying Register, read carefully Epicycle

Returns

Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.

Clear all

Showing returns filed by Novartis Ireland Limited .

Filed returns
23
match these filters
Matching filed returns per period 0 1 2 3 5 May–Aug 2016: 1 filed returns May–Aug 2017: 1 filed returns Sep–Dec 2020: 1 filed returns Jan–Apr 2022: 1 filed returns Jan–Apr 2024: 2 filed returns May–Aug 2024: 1 filed returns Sep–Dec 2024: 1 filed returns Jan–Apr 2025: 2 filed returns May–Aug 2025: 5 filed returns Sep–Dec 2025: 3 filed returns Jan–Apr 2026: 3 filed returns May–Aug 2026: 2 filed returns 2022 2024 2025 2026
Filed returns per four-month period Click a column to list its returns.
PeriodRegistrantPolicy areaSubject, as filedOfficials namedLink
May–Aug 2026 Novartis Ireland Limited Health Valuing Innovation & Advanced Cancer Therapy - policy and access (Public policy or programme) 27 On lobbying.ie
May–Aug 2026 Novartis Ireland Limited Health Life Science Strategy (Public policy or programme) 4 On lobbying.ie
Jan–Apr 2026 Novartis Ireland Limited Health National Life Sciences Strategy (Public policy or programme) 2 On lobbying.ie
Jan–Apr 2026 Novartis Ireland Limited Health IIEA event on EU Presidency and Public Health (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2026 Novartis Ireland Limited Health Supporting a Health Policy Partnership Initiative for them to run a roundtable and draft a white paper with policy stakeholders. (Public policy or programme) 26 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health Forwarding letter to Dept of Health about access to innovative treatment for Irish patients (Public policy or programme) 6 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health World Urticaria Day event (Public policy or programme) 4 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health Advocate for Life Science Strategy (Public policy or programme) 7 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Health Launch of the Rare Disease National Strategy at Department of Health (Public policy or programme) 1 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Health Letter to Tanaiste about access to innovative treatment for Irish patients (Public policy or programme) 5 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Health IIEA event with a panel of speakers about Developing a National Life Sciences Vision for Ireland (Public policy or programme) 1 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Health Implementation of SMA onto the Heel prick test (Matters involving public funds) 1 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Health Rare diseases conference, as an official event of the Irish EU Presidency (Public policy or programme) 6 On lobbying.ie
Jan–Apr 2025 Novartis Ireland Limited Health Timely inclusion of SMA in heal prick test (Matters involving public funds) 1 On lobbying.ie
Jan–Apr 2025 Novartis Ireland Limited Health Reimbursement decision for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (Matters involving public funds) 4 On lobbying.ie
Sep–Dec 2024 Novartis Ireland Limited Health Implementation of SMA testing into the heel prick test for newborns (Matters involving public funds) 7 On lobbying.ie
May–Aug 2024 Novartis Ireland Limited Health Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) 25 On lobbying.ie
Jan–Apr 2024 Novartis Ireland Limited Health Newborn screening for spinal muscular atrophy (SMA) is implemented for babies in Ireland (Matters involving public funds) 6 On lobbying.ie
Jan–Apr 2024 Novartis Ireland Limited Environment EU Mercury Committee to approve a process which is a more efficient use of scarce raw materials (Matters involving public funds) 2 On lobbying.ie
Jan–Apr 2022 Novartis Ireland Limited Health Update of SmartD8 Heart of Our City Social Prescribing Project. Discussion on national Illness/wellness festival with Healthy Ireland support. Partnerships/collaborations to support the Healthcare system. (Matters involving public funds) 1 On lobbying.ie
Sep–Dec 2020 Novartis Ireland Limited Health Expansion of Newborn Screening (Legislation) 2 On lobbying.ie
May–Aug 2017 Novartis Ireland Limited Health Highlight delay in reimbursing Entresto (Heart Failure medine), the first new innovation in heart failure in a decade considered cost effective in July 2016 (Matters involving public funds) 23 On lobbying.ie
May–Aug 2016 Novartis Ireland Limited Health Ensure that the 2016 Framework Agreement on the Pricing and Supply of Medicines is resolved by aggreement, not legislation (Public policy or programme) 5 On lobbying.ie

Policy areas in these returns

Public policy areaFiled returnsShareRelative to the largest
Health 22 95.7%
Environment 1 4.3%